Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment:...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Nonexudative age-related macular degeneration (AMD) is a leading cause of vision loss.
• Current treatments for nonexudative AMD are limited.
• Risuteganib is an investigational drug being studied for its potential therapeutic effects in AMD.

Purpose of the Study:

• To investigate the association between improvements in best-corrected visual acuity (BCVA) and changes in microperimetry (MP) and color vision.
• To evaluate the efficacy of risuteganib in patients with nonexudative AMD.

Main Methods:

• A prospective, double-masked, sham-controlled phase 2a study.
• Patients with nonexudative AMD received two 1.0-mg intravitreal doses of risuteganib or sham injections.
• Exploratory endpoints included changes in color vision and mesopic MP.

Main Results:

• A significant correlation was observed between BCVA and color vision metrics (TES Lanthony and Hue Style).
• Risuteganib responders showed trends toward improvement in color vision and MP, while nonresponders did not.
• Statistically significant improvements were noted in the confusion index and the number of loci with decreased sensitivity in responders.

Conclusions:

• Risuteganib treatment demonstrated a trend toward improving visual function in patients with nonexudative AMD.
• The study provides evidence of objective and subjective improvements in retinal function.
• Further research is warranted to confirm these findings and evaluate long-term efficacy.